- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
KORU Medical Systems, Inc.(KRMD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for KRMD
11/13/2026: KRMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
KORU Medical Systems is a medical technology company specializing in portable mechanical infusion systems for subcutaneous drug delivery. Its primary strength lies in its established Freedom platform and recurring-use disposable supplies, supported by high patient adherence and expanding pharmaceutical collaborations. The main investment story centers on growth opportunities in international markets and new drug label expansions, counterbalanced by risks from intense competition, pharma bundling, and micro-cap volatility. The stock suits growth-oriented or active investors willing to monitor quarterly profitability trends, regulatory milestones, and execution progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While KORU offers expanding revenue and pipeline opportunities in subcutaneous drug delivery, its small scale and historical micro-cap profile temper pure growth appeal. |
| Momentum investor | Strong fit while signal remains positive | Recent positive earnings inflection and strong short-term price breakouts attract active momentum participants. |
| Value investor | Mixed fit | Valuation multiples remain elevated relative to current earnings maturity, though expanding profitability improves long-term fundamental support. |
| Dividend investor | Weak fit | The company does not pay dividends, directing all capital toward reinvestment and growth. |
| Low-risk investor | Weak fit | Micro-cap volatility, customer concentration, and execution risks present higher risk profiles unsuited for conservative capital preservation mandates. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a micro-cap medical technology stock, shares are susceptible to sharp price swings based on quarterly results and sentiment. |
| Valuation risk | Medium / high | Forward expectations require sustained execution to justify current valuation multiples as profitability scales. |
| Competition risk (pharma bundling and large device competitors) | High | Well-capitalized pharmaceutical and device competitors possess superior resources to bundle rival drug-delivery systems. |
| Business quality | Medium | The razor-and-blade recurring revenue model provides solid gross margins, but single-product reliance limits broader franchise breadth. |
| Dividend income | Low / none | No dividend is paid, offering zero income return for yield-focused investors. |
| Execution risk | Medium / high | Successful commercialization of new pipeline drugs and international market expansion depend heavily on flawless operational execution. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 160.49M USD | Price to earnings Ratio - | 1Y Target Price 6.12 |
Price to earnings Ratio - | 1Y Target Price 6.12 | ||
Volume (30-day avg) 190.2K shares | Beta 0.52 | 52 Weeks Range 2.86 - 6.61 | Updated Date 11/15/2026 |
52 Weeks Range 2.86 - 6.61 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Instruments & Supplies
- BUY participation
- 60.0%
- Active BUY / eligible
- 3 / 5
- 30-Day BUY Count Change
- +1
Eligible universe: 5 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 15.7% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Domestic Core | Sales of FREEDOM60 and FreedomEdge syringe infusion drivers, HIgH-Flo safety needle sets, and precision flow rate tubing in the U.S. | This is the primary engine of the company, generating recurring sales of disposable supplies every time patients perform treatments. |
| International Core | Distribution of infusion pumps and proprietary disposables across global markets via international partners and direct regulatory approvals. | Provides a secondary geographic growth avenue as international adoption of subcutaneous therapy scales up. |
| Pharma Services and Clinical Trials | Collaborating with drug developers to evaluate and integrate infusion systems for clinical trials and novel drug co-formulations. | Builds future growth pipelines by embedding KORU's technology directly into upcoming pharmaceutical drug labels. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-10 | When After Market | Estimate -0.02 | Actual 0.02 |
Profitability
Profit Margin -1.78% | Operating Margin (TTM) -1.25% |
Management Effectiveness
Return on Assets (TTM) -1.29% | Return on Equity (TTM) -4.59% |
Valuation
Trailing PE - | Forward PE 92.59 | Enterprise Value 156.41M | Price to Sales(TTM) 3.47 |
Enterprise Value 156.41M | Price to Sales(TTM) 3.47 | ||
Enterprise Value to Revenue 3.38 | Enterprise Value to EBITDA 786.59 | Shares Outstanding 43.38M | Shares Floating 31.62M |
Shares Outstanding 43.38M | Shares Floating 31.62M | ||
Percent Insiders 8.77 | Percent Institutions 58.59 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

